CHIGENOVO

Changping District, China Founded: 2016 • Age: 10 yrs
Gene therapy drugs for inherited eye diseases are developed.
Annual revenue - Latest available
Total funding $26.5M 3 rounds
Employees - Tracked headcount
Investors 7 Known backers
Products 2 Services tracked
Competitors - Brand Intelligence

About CHIGENOVO

CHIGENOVO is a company based in China founded in 2016. CHIGENOVO has raised $26.45 million across 3 funding rounds from investors including Kunlun Capital, Gimpo Investment and Yingke Capital. CHIGENOVO offers products and services including Gene Therapy Drugs and Gene Diagnosis Services.

  • Headquarter Changping District, China
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Legal Name 北京中因科技有限公司
  • Jurisdiction Na, Maharashtra, India
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $26.45 M (USD)

    in 3 rounds

  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of CHIGENOVO

CHIGENOVO offers a comprehensive portfolio of products and services, including Gene Therapy Drugs and Gene Diagnosis Services.

Product name locked
Category locked
Primary

Gene therapy drugs for hereditary eye diseases are developed and evaluated.

Product name locked
Category locked
Locked

Precise genetic diagnosis for eye diseases is offered through sequencing and analysis.

Funding Insights of CHIGENOVO

CHIGENOVO has successfully raised a total of $26.45M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in CHIGENOVO

CHIGENOVO has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Kunlun Capital, Gimpo Investment and Yingke Capital.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investments in technology companies are managed by Kunlun Capital.
Locked Locked Locked
-
Locked Locked Locked
-
Locked Locked Locked
Premium access

Investor details for CHIGENOVO

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by CHIGENOVO

Investments
Premium access

Investment portfolio details for CHIGENOVO

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - CHIGENOVO

Premium access

Detailed financials for CHIGENOVO

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Chigenovo Comparisons

CHIGENOVO Primary company
Description
Gene therapy drugs for inherited eye diseases are developed.
Location
China
Founded Year
2016
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for CHIGENOVO

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of CHIGENOVO

Premium access

Detailed competitors of CHIGENOVO

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Chigenovo

Premium access

Complete news archive for CHIGENOVO

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about CHIGENOVO

CHIGENOVO was founded in 2016 and raised its 1st funding round 5 years after it was founded.

CHIGENOVO is headquartered in China. It is registered at Beijing, China.

CHIGENOVO is a funded company, having raised a total of $26.45M across 3 funding rounds to date.

CHIGENOVO was founded in 2016 and is located in Changping District, China. Operations are centered in the biotechnology sector, where gene therapy drugs for inherited eye diseases are developed alongside genetic diagnosis services. Focus is placed on high-tech advancements to address these conditions through innovative therapeutic and diagnostic approaches. The company operates as a specialized enterprise in this niche.

CHIGENOVO offers Gene Therapy Drugs and Gene Diagnosis Services.

CHIGENOVO has 7 investors. Key investors include Kunlun Capital, Gimpo Investment, Yingke Capital, Huayi Capital, and Junci Investment.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available